Clinical trials: PET/CT, open to volunteers
Multiple Myeloma
Comparison Between Whole Body DWI and FDG PET/CT in Patients with Simptomatic Multiple Myeloma
The primary objective is to evaluate the concordance of FDG PET/CT and total body DWI MRI sequences performed during staging and at the completion of therapy.
- Trial name
- MMR-PET-22-04 (NCT06659276)
- Where
- Italy
- Volunteers
- 83 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Oncologic Diseases
Implications of Biological and Procedural Factors of 18-f FDG Uptake by Normal Organs and Neoplastic Lesions
To evaluate implications of biological and procedural factors of 18-f FDG PET/CT uptake on normal organs and neoplastic lesions.
- Trial name
- NCT06626932
- Testing
- 18 FDG (Fludeoxyglucose 18F)
- Where
- Egypt
- Volunteers
- 259 people
- Sponsor
- mahenoor alaa eldeen naem
Prostate Cancer (Adenocarcinoma)
Impact of [18F] PSMA-1007 Imaging for Primary Staging of Prostate Cancer
The introduction of PSMA diagnostics and therapy has fundamentally changed the treatment management of prostate cancer and has significantly replaced other clinical and radiological diagnostic methods.
- Trial name
- NCT06820333
- Where
- Germany
- Volunteers
- 200 people
- Sponsor
- Heinrich-Heine University, Duesseldorf
Solitary Pulmonary Nodule, Oncology
18F-2-fluoro-2-deoxy-D-glucose in Positron Emission Tomography Computed Tomography
The study objectives are as follows: To determine the safety of trial 18F-2-fluoro-2-deoxy-D-glucose, produced by a new manufacturer, by surveillance for adverse events in patients having Positron Emission Tomography Computed…
- Conditions
- Solitary Pulmonary Nodule, Oncology, 18F-2-fluoro-2-deoxy-D-glucose, Adverse Event
- Trial name
- NCT04615156
- Testing
- 18F-2-fluoro-2-deoxy-D-glucose
- Volunteers
- 10,000 people
- Sponsor
- Eastern Health, Canada
Head and Neck Squamous Cell Carcinoma, PET/CT
PET/CT Follow up for Head and Neck Squamous Cell Carcinoma
PET/CT follow up for Head and Neck Squamous Cell Carcinoma The following is a presentation of a prospective protocol, named PET/CT follow up for Head and Neck Squamous Cell Carcinoma (PET Follow), including patients who have…
- Trial name
- PET Follow (NCT05707078)
- Testing
- Neck dissection
- Where
- Denmark
- Volunteers
- 600 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Endometriosis
The Role of FAPI PET-CT in Diagnosing Endometriosis
Patients with suspected endometriosis scheduled for surgery will be identified. They will be asked to participate in a study evaluating the feasibility of FAPI PET-CT in diagnosing endometriosis.
- Trial name
- NCT06792318
- Testing
- FAPI PET-CT
- Where
- Israel
- Volunteers
- 30 people
- Sponsor
- Ziv Hospital
Primary Aldosteronism
Baxdrostat and Molecular Imaging of Adrenal Cytoreduction in Primary Aldosteronism
The goal of this clinical trial is to find out whether treatment with baxdrostat changes aldosterone-producing activity in the adrenal glands of people with primary aldosteronism.
- Trial name
- EliXir (NCT07800858)
- Testing
- baxdrostat
- Where
- 2 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Queen Mary University of London
Soft Tissue Sarcoma
A Multicenter Phase II Clinical Trial Evaluating 68Ga-HX01 Injection for PET/CT Imaging
soft tissue sarcoma
- Trial name
- NCT07920835
- Testing
- 68Ga-HX01 Injection Solution
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Hexin (Suzhou) Pharmaceutical Technology Co., Ltd
Healthy Volunteer, Bone Alteration
Ultralow Dose PET Imaging for 18F-NaF Uptake
The goal of this clinical trial is to evaluate an investigational ultralow dose positron emission tomography (PET imaging) technique for increased bone turnover that is found in diseases such as cancer, trauma, infection…
- Conditions
- Healthy Volunteer, Bone Alteration, Bone and Joint Cancer, Bone and Joint Infection
- Trial name
- NCT07284563
- Testing
- 18F-NaF
- Where
- 2 sites in United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Akiva Mintz
Breast Cancer, Gastric Cancer (GC)
The Exploration of Novel Radionuclide-labeled HER2-targeting Antibodies in the Diagnosis of HER2-positive Malignancies
The purpose of this study is to develop and clinically evaluate 89Zr-labeled HER2-targeted antibodies in diagnosis and screening of HER2-positive cancer patients.
- Conditions
- Breast Cancer, Gastric Cancer (GC), Urothelial Carcinoma (UC)
- Trial name
- NCT07023861
- Testing
- 18F-FDG, 89Zr-LNCab190, 89Zr-LNCab002
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Affiliated Hospital of Jiangnan University
Stage III Breast Cancer
[18F]FES PET/CT for the Detection of Distant Metastasis in Low-grade ER-positive Stage III Breast Cancer
This study aims to evaluate the detection rate of distant metastases using [18F]FES PET/CT in patients with low-grade, ER-positive stage III breast cancer.
- Trial name
- NCT07314073
- Testing
- Fluoroestradiol (18F)
- Where
- South Korea
- Volunteers
- 85 people
- Sponsor
- Asan Medical Center
Abdominal Sepsis
Characterization of Abdomino-pelvic Lesions by 18Fluorine- Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography
The aim of the study is to identify and characterize lesions in the abdominopelvic region detected by 18fluorine- fluorodeoxyglucose (FDG) positron Emission Tomography combined Computed Tomography (PET/CT) scan, including…
- Trial name
- 18F-FDG PET/CT (NCT07127627)
- Testing
- PET/CT
- Volunteers
- 79 people
- Sponsor
- Assiut University
mCRPC, Male Urogenital Diseases
The Radium-select Study
Radium-223 is an established radionuclide therapy for patients with metastatic castration resistant prostate cancer (mCRPC) and symptomatic bone metastasis.
- Trial name
- NCT06659926
- Testing
- 68Ga-PSMA-PET/CT scan
- Where
- 5 sites in Netherlands
- Volunteers
- 60 people
- Sponsor
- The Netherlands Cancer Institute
Pancreatic Neoplasms, Stomach Neoplasms
PET Imaging of Solid Tumors by a Novel Tracer, 68Ga-FAPI
Cancers of the pancreas, bile ducts, stomach and ovaries are dismal diseases with most patients being diagnosed in advanced stages leading to a bad prognosis.
- Conditions
- Pancreatic Neoplasms, Stomach Neoplasms, Bile Duct Neoplasms, Epithelial Ovarian Cancer
- Trial name
- NCT05172310
- Testing
- 68Ga-FAPI-46, PET/CT
- Where
- Sweden
- Volunteers
- 410 people
- Sponsor
- Karolinska University Hospital
Brain Metastases, Adult, Brain Metastases
Assess Use of 18F-Fluciclovine for Patients With Large Brain Metastases Treated With Staged Stereotactic Radiosurgery
The spread of cancer to the brain is referred to as brain metastases. Brain metastases are a common complication of cancer. This study is being done to determine whether the use of a new imaging agent, 18F-fluciclovine, is able…
- Conditions
- Brain Metastases, Adult, Brain Metastases, Brain Cancer
- Trial name
- NCT04689048
- Testing
- 18F fluciclovine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Baptist Health South Florida
Nasopharyngeal Carcinoma (NPC), PET / CT
Precise Guidance of Adaptive Radiotherapy for Nasopharyngeal Carcinoma
This is an observational cohort study designed to (1) evaluate whether Gallium-68 (68Ga)-labeled fibroblast activation protein inhibitor ligand LM3 (68Ga-FAPI-LM3) positron emission tomography/computed tomography (PET/CT)…
- Trial name
- NCT07137052
- Where
- China
- Volunteers
- 732 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Metastatic Breast Cancer, Response Monitoring
FDG-PET/CT vs. CT for Monitoring Metastatic Breast Cancer
Several studies have shown improved sensitivity of FDG-PET/CT compared with conventional imaging for diagnosing metastatic breast cancer in retrospective and smaller prospective studies.
- Trial name
- MONITOR-RCT (NCT06877949)
- Testing
- FDG-PET/CT, CE-CT
- Where
- 11 sites in Denmark, Germany and 1 more
- Volunteers
- 420 people
- Sponsor
- Odense University Hospital
Locally Advanced Pancreatic Cancer, Borderline Resectable Pancreatic Cancer
A New Clinical Pathway for Personalized Management of Borderline Resectable and Locally Advanced Pancreatic Cancer
NORPACT-3 is a nationwide, Norwegian single arm prospective study that evaluates the resectability rates and survival in patients with borderline resectable and locally advanced pancreatic cancer who received primary…
- Conditions
- Locally Advanced Pancreatic Cancer, Borderline Resectable Pancreatic Cancer, Pancreatectomy, Chemotherapy Effect
- Trial name
- NORPACT-3 (NCT06944587)
- Testing
- Chemotherapy, Radiology, Pancreatectomy
- Where
- 5 sites in Norway
- Volunteers
- 400 people
- Sponsor
- Oslo University Hospital
Neuroendocrine Neoplasms
68Ga-NYM215 in NENs
This prospective study will evaluate the safety, biodistribution, dosimetry, and imaging performance of 68Ga-NYM215 PET/CT in patients with neuroendocrine neoplasms.
- Trial name
- NCT07835906
- Testing
- 68Ga-NYM215 PET/CT, 68Ga-DOTATATE PET/CT
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Peking Union Medical College Hospital
Advanced Prostate Cancer, Metastatic Prostate Cancer
Pilot Study for Detection of PSMA-Low CRPC-NE Tumors With Fluciclovine PET/CT
This research study is studying a positron emission tomography (PET) agent called 18F-fluciclovine to evaluate how well 18F-fluciclovine-PET scans determine the extent of advanced prostate cancer that either has low…
- Conditions
- Advanced Prostate Cancer, Metastatic Prostate Cancer, Metastatic Prostate Neuroendocrine Carcinoma
- Trial name
- NCT06062745
- Testing
- 18F-fluciclovine, PET/CT
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Brigham and Women's Hospital